{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T21:24:52Z","timestamp":1769981092808,"version":"3.49.0"},"reference-count":17,"publisher":"American Association of Psychiatric Pharmacists (AAPP)","issue":"5","license":[{"start":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T00:00:00Z","timestamp":1583971200000},"content-version":"vor","delay-in-days":193,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Drug rash with eosinophilia and systemic symptoms (DRESS) is a serious adverse drug reaction with a high mortality rate. Discontinuation of the causative agent is the primary treatment. History of DRESS may put patients at higher risk of future episodes; however, cross-reactivity between various medications is not well established. An 18-year-old African American male with a history of bipolar I disorder with psychotic features was admitted for mania on his home dose of divalproex. After 1 week, olanzapine was added for refractory symptoms, but due to elevated creatinine phosphokinase (CPK), it was subsequently discontinued, and he was started on lorazepam and lithium. One week later, the patient was transferred to the intensive care unit with elevated CPK, fever, thrombocytopenia, elevated serum creatinine, hypotension, diarrhea, mild rigidity, bilateral inducible ankle clonus, and a rash. All medications were discontinued except for lorazepam. The skin pathology report was consistent with a drug eruption, and he was started on prednisone. Given continued symptoms of mania, carbamazepine was initiated. After clinical and laboratory improvement, the patient was discharged on hospital day 59 with instructions to continue carbamazepine and lorazepam. A MEDLINE search revealed no published case reports of the successful use of carbamazepine in a patient with a history of DRESS. Information regarding cross-reactivity between medications is limited primarily to aromatic antiepileptics. In our case report, carbamazepine was successfully used in a patient with a recent episode of DRESS during olanzapine, lithium, and valproate use.<\/jats:p>","DOI":"10.9740\/mhc.2019.09.331","type":"journal-article","created":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T20:12:51Z","timestamp":1567627971000},"page":"331-335","source":"Crossref","is-referenced-by-count":3,"title":["Successful use of carbamazepine in a patient with drug rash with eosinophilia and systemic symptoms"],"prefix":"10.9740","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1869-5202","authenticated-orcid":false,"given":"Alexandra L.","family":"Bixby","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3356-0106","authenticated-orcid":false,"given":"Sarah","family":"Goldsborough","sequence":"first","affiliation":[{"name":"Psychiatry Clinical Pharmacist Specialist, Department of Pharmacy, Beaumont Health, Southfield, Michigan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0928-8939","authenticated-orcid":false,"given":"Aaron","family":"Iuppa","sequence":"first","affiliation":[{"name":"House Officer, Department of Psychiatry, Michigan Medicine, Ann Arbor, Michigan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5289-5788","authenticated-orcid":false,"given":"Andrew","family":"LeBlanc","sequence":"first","affiliation":[{"name":"Resident, Department of Psychiatry, Michigan Medicine, Ann Arbor, Michigan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5000-8834","authenticated-orcid":false,"given":"Heather E.","family":"Schultz","sequence":"first","affiliation":[{"name":"Clinical Assistant Processor, Department of Psychiatry, Michigan Medicine, Ann Arbor, Michigan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2294-2694","authenticated-orcid":false,"given":"Amy","family":"VandenBerg","sequence":"first","affiliation":[{"name":"Clinical Specialist, Psychiatry & Neurology, Department of Pharmacy, Michigan Medicine, Ann Arbor, Michigan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4719","reference":[{"issue":"5","key":"2020060307350147500_i2168-9709-9-5-331-b01","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/bjd.12501","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study","volume":"169","author":"Kardaun","year":"2013","journal-title":"Br J Dermatol"},{"issue":"6","key":"2020060307350147500_i2168-9709-9-5-331-b02","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.mayocp.2016.03.006","article-title":"Management of psychotropic drug-induced DRESS syndrome: a systematic review","volume":"91","author":"Bommersbach","year":"2016","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"2020060307350147500_i2168-9709-9-5-331-b03","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1176\/ajp.148.6.705","article-title":"The serotonin syndrome","volume":"148","author":"Sternbach","year":"1991","journal-title":"Am J Psychiatry"},{"key":"2020060307350147500_i2168-9709-9-5-331-b04","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington: American Psychiatric Association;2013.","DOI":"10.1176\/appi.books.9780890425596"},{"issue":"1","key":"2020060307350147500_i2168-9709-9-5-331-b05","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bjd.13683","article-title":"Histopathology of drug rash with eosinophilia and systemic symptoms syndrome: a morphological and phenotypical study","volume":"173","author":"Ortonne","year":"2015","journal-title":"Br J Dermatol"},{"issue":"1","key":"2020060307350147500_i2168-9709-9-5-331-b06","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1164\/rccm.2008-740ST","article-title":"An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients","volume":"183","author":"Limper","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"2020060307350147500_i2168-9709-9-5-331-b07","doi-asserted-by":"crossref","first-page":"532","DOI":"10.4103\/ijd.IJD_248_16","article-title":"Lithium-induced drug reaction with eosinophilia and systemic symptom syndrome","volume":"62","author":"Bains","year":"2017","journal-title":"Indian J Dermatol"},{"issue":"2","key":"2020060307350147500_i2168-9709-9-5-331-b08","doi-asserted-by":"crossref","first-page":"123","DOI":"10.4168\/aair.2010.2.2.123","article-title":"Comparison of the causes and clinical features of drug rash with eosinophilia and systemic symptoms and Stevens-Johnson syndrome","volume":"2","author":"Jeung","year":"2010","journal-title":"Allergy Asthma Immunol Res"},{"key":"2020060307350147500_i2168-9709-9-5-331-b09","unstructured":"US Food and Drug Administration (FDA). FDA drug safety communication: FDA warns about rare but serious skin reactions with mental health drug olanzapine (Zyprexa, Zyprexa Zydis, Zyprexa Relprevv, and Symbyax) [Internet]. Silver Spring (MD): FDA. 2016[cited 2018 Apr 1]. Available from: https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm499441.htm"},{"issue":"5","key":"2020060307350147500_i2168-9709-9-5-331-b10","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S1081-1206(10)61103-9","article-title":"Anticonvulsant hypersensitivity syndrome: cross-reactivity with tricyclic antidepressant agents","volume":"97","author":"Seitz","year":"2006","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2-3","key":"2020060307350147500_i2168-9709-9-5-331-b11","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.eplepsyres.2008.04.003","article-title":"Cross-reactivity pattern of rash from current aromatic antiepileptic drugs","volume":"80","author":"Alvestad","year":"2008","journal-title":"Epilepsy Res"},{"issue":"4","key":"2020060307350147500_i2168-9709-9-5-331-b12","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s00228-013-1627-0","article-title":"The use of three-dimensional similarity in assessing the risk of cross-reactivity between carbamazepine and psychotropic drugs","volume":"70","author":"Le Louarn","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"2020060307350147500_i2168-9709-9-5-331-b13","first-page":"60","article-title":"Suspicion of a new cross-reaction between carbamazepine and olanzapine","volume":"24","author":"Brajon","year":"2014","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"4","key":"2020060307350147500_i2168-9709-9-5-331-b14","doi-asserted-by":"crossref","first-page":"518","DOI":"10.4306\/pi.2017.14.4.518","article-title":"Neosensitization to multiple drugs following valproate-induced drug reaction with eosinophilia and systemic symptoms syndrome","volume":"14","author":"Song","year":"2017","journal-title":"Psychiatry Investig"},{"issue":"5","key":"2020060307350147500_i2168-9709-9-5-331-b15","first-page":"321","article-title":"Drug neosensitization during anticonvulsant hypersensitivity syndrome","volume":"16","author":"Gaig","year":"2006","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"2","key":"2020060307350147500_i2168-9709-9-5-331-b16","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1365-2125.2010.03685.x","article-title":"Hypersensitivity to amoxicillin after drug rash with eosinophilia and systemic symptoms (DRESS) to carbamazepine and allopurinol: a possible co-sensitization","volume":"70","author":"Ben Fredj","year":"2010","journal-title":"Br J Clin Pharmacol"},{"issue":"4 Suppl","key":"2020060307350147500_i2168-9709-9-5-331-b17","first-page":"1","article-title":"Practice guideline for the treatment of patients with bipolar disorder (revision)","volume":"159","author":"American Psychiatric Association","year":"2002","journal-title":"Am J Psychiatry"}],"container-title":["Mental Health Clinician"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/mhc\/article-pdf\/9\/5\/331\/2427763\/mhc_2019_09_331.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/mhc\/article-pdf\/9\/5\/331\/2427763\/mhc_2019_09_331.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T16:25:54Z","timestamp":1731687954000},"score":1,"resource":{"primary":{"URL":"https:\/\/mhc.kglmeridian.com\/view\/journals\/mhcl\/9\/5\/article-p331.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,1]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,9,1]]}},"URL":"https:\/\/doi.org\/10.9740\/mhc.2019.09.331","relation":{},"ISSN":["2168-9709"],"issn-type":[{"value":"2168-9709","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,1]]}}}